Symptomatic non-erosive gastroesphageal reflux disease

Also known as: Symptomatic Non-erosive Gastroesophageal Reflux Disease

Drug	Drug Name	Drug Description
DB05351	Dexlansoprazole	A proton pump inhibitor used to treat erosive esophagitis, heartburn, and gastroesophageal reflux disease (GERD).
DB00927	Famotidine	A histamine H2 receptor antagonist used to treat duodenal ulcers, benign gastric ulcers, GERD, and Zollinger-Ellison syndrome.

Drug	Drug Name	Target	Type
DB05351	Dexlansoprazole	Potassium-transporting ATPase alpha chain 1	target
DB05351	Dexlansoprazole	Cytochrome P450 2C19	enzyme
DB05351	Dexlansoprazole	Cytochrome P450 3A4	enzyme
DB05351	Dexlansoprazole	Potassium-transporting ATPase subunit beta	target
DB05351	Dexlansoprazole	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	target
DB00927	Famotidine	Histamine H2 receptor	target
DB00927	Famotidine	Solute carrier family 22 member 2	transporter
DB00927	Famotidine	Solute carrier family 22 member 8	transporter
DB00927	Famotidine	Multidrug and toxin extrusion protein 1	transporter
DB00927	Famotidine	Cytochrome P450 1A2	enzyme
DB00927	Famotidine	Solute carrier family 22 member 6	transporter

Drug	Drug Name	Phase	Status	Count